Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA

Blood (2019) 134 (Supplement_1): 4087.

https://doi.org/10.1182/blood-2019-131563

Published: 2019

Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 3901.

https://doi.org/10.1182/blood-2019-131817

Published: 2019

Journal Articles

Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia

Elizabeth Rogers, PharmD, MPH, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 5134.

https://doi.org/10.1182/blood-2019-131328

Published: 2019

Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2658.

https://doi.org/10.1182/blood-2019-129377

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Meagan Scott, PharmD, Maho Hibino, PharmD, Marie Cavalier, PharmD, Bayard L. Powell, MD, Dianna S. Howard, MD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Susan Lyerly, P.A.-C., Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 2091.

https://doi.org/10.1182/blood.V130.Suppl_1.2091.2091

Published: 2017

Journal Articles

Pyruvate Dehydrogenase (PDH) Activity Is a Source of Resistance to Sorafenib in FLT3-ITD Expressing Acute Myeloid Leukemia (AML)

Rebecca G. Anderson, B.S., Kristin M. Pladna, M.S., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 3829.

https://doi.org/10.1182/blood.V130.Suppl_1.3829.3829

Published: 2017

Journal Articles

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Timothy S Pardee, MD PhD, Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2017) 130 (Supplement 1): 2626.

https://doi.org/10.1182/blood.V130.Suppl_1.2626.2626

Published: 2017

Journal Articles

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

Margaux Wooster, B.S., Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Megan Manuel, M.S.N, Rupali Bhave, MD, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD, Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 5044.

https://doi.org/10.1182/blood.V130.Suppl_1.5044.5044

Published: 2017

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2014) 124 (21): 3744.

https://doi.org/10.1182/blood.V124.21.3744.3744

Published: 2014

NARROW

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Pyruvate Dehydrogenase (PDH) Activity Is a Source of Resistance to Sorafenib in FLT3-ITD Expressing Acute Myeloid Leukemia (AML)

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only